Repare Therapeutics Inc. (RPTX): Price and Financial Metrics

Repare Therapeutics Inc. (RPTX): $9.70

-0.38 (-3.77%)

POWR Rating

Component Grades














  • Value is the dimension where RPTX ranks best; there it ranks ahead of 90.68% of US stocks.
  • The strongest trend for RPTX is in Value, which has been heading up over the past 179 days.
  • RPTX ranks lowest in Momentum; there it ranks in the 4th percentile.

RPTX Stock Summary

  • Price to trailing twelve month operating cash flow for RPTX is currently 1,315.91, higher than 99.77% of US stocks with positive operating cash flow.
  • For RPTX, its debt to operating expenses ratio is greater than that reported by only 8.75% of US equities we're observing.
  • Revenue growth over the past 12 months for REPARE THERAPEUTICS INC comes in at 1,634.61%, a number that bests 99.49% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to REPARE THERAPEUTICS INC, a group of peers worth examining would be CMRX, OMGA, BOLT, ARCT, and PSTX.
  • To dig deeper into the stock's financial statements, go to RPTX's page on browse-edgar?action=getcompany&CIK=0001808158.

RPTX Valuation Summary

  • RPTX's EV/EBIT ratio is -18.6; this is 383.97% lower than that of the median Healthcare stock.
  • Over the past 33 months, RPTX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RPTX.

Stock Date P/S P/B P/E EV/EBIT
RPTX 2023-03-17 3.1 1.5 -14.2 -18.6
RPTX 2023-03-16 3.2 1.5 -14.7 -19.7
RPTX 2023-03-15 3.2 1.5 -14.4 -19.0
RPTX 2023-03-14 3.3 1.6 -15.0 -20.2
RPTX 2023-03-13 3.3 1.5 -14.8 -19.9
RPTX 2023-03-10 3.1 1.5 -14.1 -18.4

RPTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RPTX has a Quality Grade of D, ranking ahead of 8.52% of graded US stocks.
  • RPTX's asset turnover comes in at 0.002 -- ranking 426th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RPTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -4.742
2021-03-31 0.001 1 -4.174
2020-12-31 0.000 1 -4.813

RPTX Price Target

For more insight on analysts targets of RPTX, see our RPTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $47.63 Average Broker Recommendation 1.45 (Moderate Buy)

RPTX Stock Price Chart Interactive Chart >

Price chart for RPTX

RPTX Price/Volume Stats

Current price $9.70 52-week high $18.68
Prev. close $10.08 52-week low $8.06
Day low $9.57 Volume 78,800
Day high $10.20 Avg. volume 137,019
50-day MA $11.34 Dividend yield N/A
200-day MA $13.26 Market Cap 408.16M

Repare Therapeutics Inc. (RPTX) Company Bio

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded by Daniel Durocher, Agnel Sfeir and Frank Sicheri on September 6, 2016 and is headquartered in Saint-Laurent, Canada.

RPTX Latest News Stream

Event/Time News Detail
Loading, please wait...

RPTX Latest Social Stream

Loading social stream, please wait...

View Full RPTX Social Stream

Latest RPTX News From Around the Web

Below are the latest news stories about REPARE THERAPEUTICS INC that investors may wish to consider to help them evaluate RPTX as an investment opportunity.

Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

CAMBRIDGE, Mass. & MONTREAL, March 14, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned

Yahoo | March 14, 2023

Repare Therapeutics Full Year 2022 Earnings: US$0.69 loss per share (vs US$2.83 loss in FY 2021)

Repare Therapeutics ( NASDAQ:RPTX ) Full Year 2022 Results Key Financial Results Revenue: US$131.8m (up by US$124.2m...

Yahoo | March 2, 2023

Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 1, 2023

Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

CAMBRIDGE, Mass. & MONTREAL, February 28, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Yahoo | February 28, 2023

Shareholders in Repare Therapeutics (NASDAQ:RPTX) are in the red if they invested a year ago

It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

Yahoo | February 6, 2023

Read More 'RPTX' Stories Here

RPTX Price Returns

1-mo -5.00%
3-mo N/A
6-mo -18.49%
1-year -26.29%
3-year N/A
5-year N/A
YTD -34.06%
2022 -30.25%
2021 -38.51%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7765 seconds.